



## Concert Pharmaceuticals to Participate at Upcoming Investor Conferences

November 7, 2018

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 7, 2018-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:

- The Stifel 2018 Healthcare Conference on November 14, 2018, at 2:00 p.m. ET in New York, NY;
- The Jefferies 2018 London Healthcare Conference on November 15, 2018, at 11:20 a.m. GMT in London; and
- The Global Mizuho Investor Conference on December 4, 2018 in New York.

A live webcast of the Stifel and Jefferies presentations may be accessed in the [Investors](#) section of the Company's website at [www.concertpharma.com](http://www.concertpharma.com). Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the Stifel and Jefferies conference webcasts will be available on Concert's website for two weeks following the presentations.

### About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company focused on applying its [DCE Platform®](#) (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company's approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a [broad pipeline](#) of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit [www.concertpharma.com](http://www.concertpharma.com) or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181107005068/en/>

Source: Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc.  
Justine Koenigsberg, 781-674-5284  
[ir@concertpharma.com](mailto:ir@concertpharma.com)